Heart Disease & Weight-Loss Drugs: Weighing the Effectivness v. the Risk [3qj9x6P2yW6]

Heart Disease & Weight-Loss Drugs: Weighing the Effectivness v. the Risk [3qj9x6P2yW6]

| 1h 28m 28s | Video has closed captioning.

A drug called sibutramine - sold under the name Meridia in North America and Reductil, among other names, in Europe - is at the center of an international debate about how to decide if a drug is safe enough and effective enough. The latest study of sibutramine, called SCOUT, is the first of its kind for anti-obesity drugs. More than 10,000 patients in multiple countries were observed for 5 years in a randomized controlled study. Preliminary data from the trial, recently released by the FDA, showed 1.4% of participants developed more heart problems than the placebo group. This data was enough to compel The European Medicines Agency to suspend prescriptions of sibutramine. American and Canadian drug agencies beefed up the warnings that came with the drugs. The difference in action leads into a larger debate on how the potential risks of a drug weigh against its effectiveness. #ketology keto plus acv #groupon diet pills #vita keto fuel acv gummies